Dr. Tulshidas S. Patil

Associate Professor

Qualification: M. Pharm., Ph.D.

Specialization: Pharmaceutics

Email ID: tulshidas.patil@svkm.ac.in

Phone: +91-8600122079

Experience: 7.5 Years

Academic Experience:

01.07.2019 – Present:
Institute : Shri Vile Parle Kelavani Mandal’s Institute of Pharmacy, Dhule.
Position : Associate Professor

Research Experience:

01.09.2016 – 30.06.2019 (2.8 years):
Institute: Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, Mumbai, MH
Position : Ph.D. Research Scholar in Pharmaceutical Sciences

01.09.2015 – 31.08.2016 (1 year)
Company: Fusion Scientific Pvt. Ltd., Mumbai, MH
Position: Junior Research Associate F&D

Interest Areas: Development and Evaluation of Novel and Conventional Dosage forms

Research:

• Publications:
  • International: 15
• Book Chapters: 03
• Patents: 01
• Presentations:
  • International: 02
• Completed Government Funded Projects: Nil

Industry Projects:

• Completed: Nil
• Ongoing: Nil

Conferences/Workshops/Seminars attended: 40

Academic Activities:

• Ph.D.:
  • Awarded: Nil
  • Registered: Nil
• M. Pharm Guided: Nil
• B. Pharm Guided: 10

Awards:

• Recipient of Doctoral Scholarship in Pharmaceutical Sciences from SVKM’s NMIMS Deemed-to-be-University, Mumbai.
• Recipient of PG scholarship from AICTE, New Delhi.

Professional Membership:

• Life member of the Association of Pharmaceutical Teachers of India (MA/LM-2515)
• Life member of the Indian Pharmaceutical Association (MAH/DHUL/LM/0050)
• Registered Pharmacist in the Maharashtra State Pharmacy Council (192418)

Recent Publications: Name of authors, Title, Journal Name, Volume, Year with (Impact Factor).

1. Patil TS, Gujarathi NA, Aher AA, Pachpande HE, Sharma C, Ojha S, Goyal SN, and Agrawal YO. Recent Advancements in Topical Anti-Psoriatic Nanostructured Lipid Carrier-Based Drug Delivery. International Journal of Molecular Sciences 2023; 24(3):2978. [Impact factor: 6.208].

2. Gujarathi NA, Patil TS, Rane BR, Babu A, Keservani RK. Micro-and Nano-Systems in Transdermal Drug Delivery. Topical and Transdermal Drug Delivery Systems: Applications and Future Prospects, 2023; pp. 41.

3. Gujarathi NA, Bakliwal AA, Rane BR, Keservani RK, Patil TS, Tripathi M, Husain GM. Pulmonary Drug Delivery System. Topical and Transdermal Drug Delivery Systems: Applications and Future Prospects, 2023; pp. 205.

4. Agrawal YO, Husain M, Patil KD, Sodgir V, Patil TS, Agnihotri VV, Mahajan HS, Sharma C, Ojha S, Goya SN. Verapamil hydrochloride loaded solid lipid nanoparticles: Preparation, optimization, characterisation, and assessment of cardioprotective effect in experimental model of myocardial infarcted rats. Biomedicine & Pharmacotherapy 2022; 154:113429. [Impact factor: 7.419].

5. Shete MB, Patil TS, Deshpande AS, Saraogi G, Vasdev N, Deshpande M, Rajpoot K, Tekade RK. Current trends in theranostic nanomedicines. Journal of Drug Delivery Science and Technology 2022; 103280. [Impact factor: 5.062].

6. Patil TS, Deshpande AS. Design, development, and characterisation of clofazimine-loaded mannosylated nanostructured lipid carriers: 33-Box-Behnken design approach. Materials Technology 2021; 36:460-475. [Impact factor: 3.297].

7. Patil TS, Deshpande AS. Nanostructured lipid carrier-mediated lung targeted drug delivery system to enhance the safety and bioavailability of clofazimine. Drug Development and Industrial Pharmacy 2021; 47:385-393. [Impact factor: 3.727].

8. Patil TS, Deshpande AS. Mannosylated nanocarriers mediated site-specific drug delivery for the treatment of cancer and other infectious diseases: A state of the art review. Journal of Controlled Release 2020; 320:239-252. [Impact factor: 11.467].

9. Patil TS, Deshpande AS. Development of an innovative quality by design (QbD) based stability-indicating HPLC method and its validation for clofazimine from its bulk and pharmaceutical dosage forms. Chromatographia 2019; 82:579-590. [Impact factor: 2.213].

10. Patil TS, Deshpande AS. Nanocarrier Technologies for Enhancing the Solubility and Dissolution Rate of API. In Medicinal Chemistry with Pharmaceutical Product Development. Apple Academic Press. 2019; 155-234

11. Patil TS, Deshpande AS, Deshpande S, Shende P. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need. Journal of drug targeting 2019; 27:12-27. [Impact factor: 5.016].

12. Patil TS, Deshpande AS, Shende P, Deshpande S, Gaud R. Evaluation of nanocarrier-based dry powder formulations for inhalation with special reference to anti-tuberculosis drugs. Critical Reviews™ in Therapeutic Drug Carrier Systems 2019; 36: 239-276. [Impact factor: 4.889].

13. Patil TS, Deshpande AS. Nanostructured lipid carriers-based drug delivery for treating various lung diseases: a state‐of‐the‐art review. International journal of pharmaceutics 2018; 547: 209-225. [Impact factor: 6.510].

14. Patil TS, Deshpande AS. Innovative strategies in the diagnosis and treatment of tuberculosis: a patent review (2014–2017). Expert Opinion on Therapeutic Patents 2018; 28: 615-623. [Impact factor: 6.714].

15. Patil TS, Deshpande AS, Deshpande S. Critical review on the analytical methods for the estimation of clofazimine in bulk, biological fluids and pharmaceutical formulations. Critical Reviews in Analytical Chemistry 2018; 48: 492-502. [Impact factor: 5.686].